MEA Cardiovascular Therapeutic Drugs Market

Middle East & Africa Cardiovascular Therapeutic Drugs Market Size (2024 to 2029)

Middle-East & Africa Cardiovascular Therapeutic Drugs Market is estimated to be USD 8.36 billion in 2024 and is poised to reach USD 9.48 billion by 2029 growing at a CAGR of . The past several decades have witnessed huge success in the development of effective drug therapies for common cardiovascular disease. These therapies have been widely used with the rising prevalence of cardiovascular diseases resulting in the increased market for cardiovascular therapeutics.

Cardiovascular therapeutics drugs refers to the prescribed medicines and drugs for the diseases which are related to the functioning and treatment of heart and blood vessels. While cardiovascular diseases remains to be the leading cause of dead, the major reason causing cardiovascular problems include heart failure, blood clots, coronary artery diseases, high cholesterol and others.

Cardiovascular diseases remains the common cause of mortality and morbidity across the globe and is an emerging threat. The driving factors for the cardiovascular therapeutics includes growing per capita medical spending, rising aging population and epidemic of general medical problems which includes obesity and diabetes. However, there are few restraints faced by the market which includes high costs involving drug development and lowering of target population. Cardiovascular diseases remains the common cause of mortality and morbidity across the globe and is an emerging threat. Despite its extensive existence, many of the drug development pipelines has been stagnant for variety of factors.

Middle-East & Africa cardiovascular therapeutic drugs market is segmented based on the type of disease and drug class. The market based on the disease is further segmented into Arteriosclerosis, Cardiac arrhythmias, Myocardial infarction, acute coronary syndrome, Peripheral artery disease, Coronary artery disease, hypertension, hyperlipidemia, thrombosis, cardiac failure diseases and other cardiovascular diseases. Based on the drug class, the market is segmented into monotherapies and combination drug classes. Based on geography, market is segmented into Saudi Arabia, UAE, Israel, Africa and others.

Some of the leading companies in Cardiovascular Therapeutics Drugs Market includes Johnson & Johnson, Bayer, AstraZeneca, Novartis, Bristol-Myers Squibb, Takeda, Merck, Pfizer Sanofi, and Boehringer Ingelheim.